Navigation Links
Evidence of Nanoparticles Found in Plaque-Filled Arteries

ROCHESTER, Minn., April 30. 2007-- Scientific evidence increasingly links arterial calcification to the presence of nanosized particles -- so small that some scientists question whether a nanoparticle can live and, if so, play a viable role in causing disease.

A new Mayo Clinic study cites evidence showing the presence of nanoparticles near plaque-filled arteries in animal models. The study suggests that nanoparticles potentially represent a previously unrecognized factor in the development of arteriosclerosis and calcific arterial disease. The study will be presented during the 2007 Experimental Biology meeting in Washington, D.C., on April 29.

Calcium deposits clog blood vessels and damage major organs, such as the heart. But the molecular mechanisms that kick-start this process, called pathologic calcification, haven't been explained.

The study's author, Maria Kraemer, a Mayo Graduate School student in Rochester, Minn., and colleagues isolated and propagated self-replicating, self-calcifying nanoparticles from human arteriosclerotic aneurysms and kidney stones.

"The work we are doing with human-derived nanoparticles is important because preliminary studies indicate that they may increase negative responses to arterial injury, possibly leading to blocked arteries and arterial calcification," Kraemer says.

Researchers tested their hypothesis by inoculating animal models with nanoparticles from human calcified tissues. A second group of models received a diluted inoculation. Blocked arteries were apparent in some animals in both groups 35 days after receiving the dosage.

This study was funded by Nanobac Pharmaceuticals, Inc., and Mayo Clinic.

# # #

Experimental Biology is an annual scientific meeting convened by the Federation of American Societies of Experimental Biology, including the American Association of Anatomists; American Physiological Socie ty; American Society for Biochemistry and Molecular Biology; American Society for Investigative Pathology; American Society for Nutrition; and the American Society for Pharmacology and Experimental Therapeutics.


'"/>




Related medicine technology :

1. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
2. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
3. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
4. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
5. British Journal of Cancer Reports Preclinical Evidence of Positive Effect of Rice Bran on Intestinal Cancer
6. Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA Nanoparticles
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
9. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
10. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
11. The International Myeloma Foundation Reports Positive Shift In Treatment Paradigm For Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):